Search Results

 

You need to login or register to view this content

All our reports and results are available free of charge personal use, and/or non-commercial use, however, you must first register with us to view our data.

View full Terms and Conditions



Log In

Respondent CDP 2008: Pfizer Inc.

General Information
<>It requirement CDP questionnaire introduction answer like text box attach document
Climate Change Energy Integral Corporate ResponsibilityAs pharmaceutical company advance good health innovation production distribution medicines preservation creation healthy environment Pfizer committed protecting environment health safety colleagues communities operate world seek identify emerging environmental issues relevant pharmaceutical biotechnical industry stakeholders lead efforts address strategically tactically innovative policies technology programs environmental leader Pfizer company standard requiring conservation energy reduction GHG 1996 larger effort reduce footprint company developed integrated strategic Energy Climate Change Program seek minimize cost operational restrictions arising carbon constrained environment reduce GHG emissions adapt changes warming global climate ensure rigorous compliance applicable laws committed reduction greenhouse gases viable energy alternatives effects environment mind Goals Commitments meet 35 percent electricity needs 2010 use "cleaner" energy technologies generation reduce CO2 emissions 35 percent $US MM revenue 2007 baseline year 2000 reduce impacts nearly 33 000 automobiles worldwide effectively manage financial implications opportunities associated energy reductions gleaned conservation clean energy projectsTo identify operating risks business opportunities presented changing global climate***Pfizer set new public goal reducing carbon dioxide emissions 20 percent absolute basis 2008 2012 (baseline 2007)

 
<>Where available provide following identification numbers primary listings/ordinary shares information company Company Turnover (also known sales) millions US$
48418

 
<>ISIN number

 
<>CUSIP number

 
<>SEDOL number

 
1 - Risks and Opportunities
Question 1(a)(i) Regulatory Risks
<>How company exposed regulatory risks related climate change
We consider our company to be exposed to regulatory risks because... 
Europe Pfizer subject European Union Emission Trading Scheme (EU ETS) currently mandatory regulation applicable Pfizer operations Pfizer facilities Europe affected Phase 1 ETS energy conservation efforts new entrant allowances Pfizer excess allocation facilities able provide facilities EU Pfizer did experience major direct impact Phase EU ETS Phase 2 Pfizer’ s plants Scheme facility divestitures Pfizer does anticipate Phase II major direct impact operations covered facilities additional Pfizer facilities included Phase II power purchase operate Europe impacted costs allowances power generators required purchase Pfizer believes future regulations mandatory scheme include incentives businesses reduce energy use current design EU ETS scheme example does provide credit early reduction emissions credit energy efficiency reduction indirect emissions CO2 characteristics credit reductions indirect emissions act disincentive industry investment higher efficiency cogeneration demand opportunities United States moving implementation climate change legislation details timing future regulation carbon emissions United States uncertain regulation area likely require regulated entities significantly reduce GHG emissions capital improvements purchase allowances offsets Additionally federal legislation increase operating costs regulated unregulated entities Lack harmonization state requirements initiatives federal legislation pose additional burden facilities mandated comply potentially different requirements aimed achieve basically objective e reduction GHG emissions

 
<>Would like provide additional information relating question provided
No 

 
Question 1(a)(ii) Physical Risks
<>How company exposed physical risks climate change
We consider our company to be exposed to physical risks because... 
pharmaceutical company develop manufacture product direct impact global climate change impacts indirect (i e GHG emissions impact results research manufacture transport sale Pfizer product market) Pfizer global company standard requiring conservation energy reduction greenhouse gases 1996 Sea level rise frequent intense weather events potentially expose facilities supply chain physical risks flooding business interruption facility locations existing distribution networks believe risks significant near term Pfizer’ s business model continues evolve expand (e g outsourcing key suppliers distribution centers) issues need consider potential impact climate change adverse weather patterns changing operations including stand facilities supply chain logistics related potential business interruption ability deliver medicines markets

 
<>Would like provide additional information relating question provided
No 

 
Question 1(a)(iii) General Risks
<>How company exposed general risks result climate change
We consider our company to be exposed to general risks because... 
EU ETS developed reduce GHG emissions Europe continues present risk higher costs energy general commercial risks associated sale purchase carbon instruments CERs EECs RECs especially voluntary market regulation regarding quality origin credits Recent information suggests viability Clean Development Mechanisms (CDMs) market value CERs tenuous factors suggested considerably high rate error respect validation verification CERs specifically actual number CERs generated projects overestimated noted challenges regarding CERs include regulatory uncertainty regarding use past 2012 expiration date Kyoto Protocol limited price visibility substantial lead time project line register verify CERs example concern excess emissions allowances currently held Russia Ukraine flood market sink prices allowed dispose allowances market 2008 included (ii iv v)

 
<>Would like provide additional information relating question provided
No 

 
Question 1(a)(iv) Risk Management
<>Has company taken planned action manage general regulatory risks and/oradapt physical risks identified
We have taken or planned action. 
Relative regulatory risks Pfizer’ s Global Energy Climate Change Team tracks salient legislative proposals applicable landmark court decisions subsequent regulatory directive pertinent issues summaries internal stakeholders order best position Company carbon constrained environment example Team actively tracking development federal climate change legislation (in particular S 2191) determine applicability Pfizer operations Relative general commercial risks associated transactions carbon markets evaluating investment energy efficiency projects purchase sale various carbon instruments Pfizer determined necessary look carefully project and/or instrument generated understand attributes offered project help achieve Pfizer’ s goal reducing emissions example determination credits generated project additional critical transfer title attributes represented instrument question determined necessary understand purchase sale entitles Pfizer reduce GHG emissions increase renewable energy consumption circumstances double counting reduction occur double counting avoided accounting actual emissions meeting voluntary goals Relative increasing energy costs Pfizer believes energy efficiency projects initiatives continue effective way manage energy costs reduce GHG emissions Pfizer believes renewable energy projects offer opportunities protect rising energy costs consideration energy project financial review Relative physical risks result sea level rise increase adverse weather events Pfizer does believe risks significant operations near term intends conduct refined assessment risks future

 
<>Would like provide additional information relating question provided
No 

 
Question 1(a)(v) Financial Business implications
<>How assess current and/or future financial effects therisks identified risks affect business
We assess current and/or future financial effects by... 
Pfizer’ s Energy Climate Change Program reduces company’ s contribution GHG emissions seeks minimize cost energy provides renewable energy alternatives second generation GHG emissions reduction goals goal use 35% cleaner energy objectives Green Buildings Green Chemistry teams voluntary measures continue reduce financial implications operating carbon restricted world anticipate continued effective implementation worldwide energy climate change program continue limit potentially adverse economic impact Pfizer measures taken address climate change expect seen increase cost energy result supply constraints tax levies environmental restrictions related fuel switching prefer view market impacts opportunities advance demand management projects lamping projects HVAC upgrades cogeneration projects

 
<>Would like provide additional information relating question provided
No 

 
Question 1(b)(i) Regulatory Opportunities
<>How current anticipated regulatory requirements climate change offeropportunities company
We consider that current or anticipated regulatory requirements offer opportunities because... 
extent developing regulatory requirements early action account Pfizer positioned advantage credits incentives provided new regulatory frameworks based efforts reduce GHG emissions date including second generation GHG emissions reduction goals Pfizer recognizes energy conservation efficiency improvements offer significant cost savings opportunities monetize value GHG reductions turn used turn non financially viable energy efficiency clean energy projects financially viable projects various mandatory voluntary GHG markets developing worldwide present opportunities companies advantage value GHG reductions offer 2000 2007 engaged 1 000 clean energy energy efficiency projects sites projects generated emission reductions energy efficiency credits qualified sale mandatory voluntary markets example recently manufacturing plant Thane India completed project convert residual fuel oil fired boilers enable burn renewable biomass briquettes agricultural residue generate CERs sale noted (a (iii)) Pfizer acknowledges generation sale CERs credits affect company’ s ability count project voluntary goals addition sale credits incentives available tax credits grants energy efficiency renewable energy projects Pfizer evaluates project scoping

 
<>Would like provide additional information relating question provided
No 

 
Question 1(b)(ii) Physical Opportunities
<>How current anticipated physical changes resulting climate change presentopportunities company
We consider that current or anticipated physical changes offer opportunities because... 
Based current understanding climate change anticipated physical changes result carefully evaluating operating plans potential business opportunities

 
<>Would like provide additional information relating question provided
No 

 
Question 1(b)(iii) General Opportunities
<>How does climate change present general opportunities company
We consider that climate change offers opportunities because... 
Included b (ii iv v)

 
<>Would like provide additional information relating question provided
No 

 
Question 1(b)(iv) Maximizing Opportunities
<>Do invest plans invest products services designedto minimize adapt effects climate change
Climate change has led to investment or planned investment in order to maximise climate change opportunities. 
Climate change impacts likely increase importance access medicines certain diseases Pfizer’ s continued commitment improving access medicines positive impact relative potential need

 
<>Would like provide additional information relating question provided
No 

 
Question 1(b)(v) Financial Business Implications
<>How assess current and/or future financial effects theopportunities identified opportunities affect business
We assess current and/or future financial effects by... 
Effectively managing financial implications opportunities associated energy reductions gleaned conservation clean energy projects important component program continued efforts evaluate undertake projects offer opportunities generate carbon credits (e g EECs RECs) preparation emissions trading programs advantage incentives offered

 
<>Would like provide additional information relating question provided
No 

 
2 - Greenhouse Gas (GHG) Emissions Accounting
Question 2(a)(i) Reporting Boundary
Calculation tools assist companies calculating GHG emissions particular activities combustion fuels production processes http //www ghgprotocol org/calculation tools/all tools Companies new emissions reporting strongly recommended use tools assist calculations used calculation tool list question methodologies
<>Please indicate category best describes company entities groupfor response prepared
Other 
Pfizer’ s calculations GHG emissions completed referencing WRI GHG Protocol using operational control organizational boundary approach materiality threshold 5% data based invoices purchased quantities electricity coal fuel oil natural gas steam fleet aviation fuels

 
<>Would like provide additional information relating question provided
No 

 
Question 2(a)(ii) Reporting Year
<>Please explicitly state dates accounting year period GHG emissionsare reported
Start date 01 January 2007End date 31 December 2007Financial accounting year 01 January 2007

 
<>Would like provide additional information relating question provided
No 

 
Question 2(a)(iii) Methodology
<>Please specify methodology used company calculate GHG emissions select methodology used using radio buttons used GHG Protocol ISO 14064 1 references calculation tools used explanation calculation methods devised explain data sources Global Warming Potentials emission factors used calculations reference supplied calculation tool contact provider calculation tool information used methodology devised explain methodology including methods calculation data sources Global Warming Potentials emission factors
GHG Protocol 
follow WRI GHG accounting protocol calculate GHG emissions protocol’ s salient requirements captured Inventory Management Plan (IMP) approved USEPA’ s Climate Leaders program June 2007 IMP guides calculation process

 
<>Would like provide additional information relating question provided
No 

 
Question 2(b)(i) Scope 1 Scope 2 GHG Protocol
<>Are able provide breakdown direct indirect emissions Scopes 1 2 GHG Protocol analyse electricity consumption

 
<>Would like provide additional information relating question provided
Yes 
able provide breakdown Scope 1 2 emissions operations meet operational control test Details Scope 1 2 emissions presented graphical form [REFER ATTACHMENT Graphs][REFER ATTACHMENT C Tables]

Download attachment
Download attachment
 
Question 2(b)(i)(y) Scope 1 Scope 2 GHG Protocol Year 1 answers
<>Please enter dates reporting period specified (answer question 2(a)(i)) answer questions period selecting “ Add Additional Year Figures” button end webpage repeat process previous reporting period reporting period possible data going reporting period ending 2004 enter historical data reported information response previous CDP questionnaires

 
<>Please enter accounting year used report GHG emissions details
Start date 01 January 2007End date 31 December 2007

 
<>Scope 1 Direct GHG Emissions provide Total global Scope 1 activity Metric Tonnes CO2 e emitted
<>1058047 CO2e metric tonnes < text="">

 
<>b Total Scope 1 activity Metric Tonnes CO2 e emitted Annex Bcountries
<>977036 CO2e metric tonnes < text="">

 
<>By country Scope 1 activity metric tonnes CO2 e individual country Using methodology state emissions country NB practical list emissions country country basis list countries significant emissions context business combine remainder “ rest world” information format (e g Excel) attach
Country Scope 1 Emissions
(metric tonnes CO2-e)

 
<>Scope 2 Indirect GHG emissions provide c Total global Scope 2 activity metric tonnes CO2 e emitted
<>1136126 CO2e metric tonnes < text="">

 
<>d Total Scope 2 activity metric tonnes CO2 e emitted Annex Bcountries
<>1030375 CO2e metric tonnes < text="">

 
<>By country Scope 2 activity metric tonnes CO2 e individual country
Country Scope 2 Emissions
(metric tonnes CO2-e)

 
<>Electricity consumptione Total global MWh purchased electricity
1960212 MWh

 
<>f Total MWh purchased electricity Annex B countries
1774317 MWh

 
<>By country – MWh purchased electricity individual country
Country

 
<>g Total global MWh purchased electricity renewable sources
48900 MWh

 
<>h Total MWh purchased electricity renewable sources Annex Bcountries
45587 MWh

 
<>By country – MWh purchased electricity renewable sources individual country
Country

 
<>Would like provide additional information relating question provided
Yes 
[REFER ATTACHMENT C Tables]

Download attachment
 
Question 2(b)(ii) Scopes 1 2 GHG Protocol
<>If unable Scope 1 Scope 2 GHG emissions and/or electricity consumption report GHG emissions able identify description emissions answered 2(b)(i) question 2(c)(i)

 
<>Would like provide additional information relating question provided

 
Question 2(c)(i) Emissions – Scope 3 GHG Protocol
<>How identify and/or measure Scope 3 emissions
changes business model includes increased outsourcing Pfizer currently process conducting detailed analysis overall carbon footprint related Scope 3 emissions including emissions employee business travel employee commuting supply chain relates suppliers key pharmaceutical ingredients logistics distribution activities disposal products results evaluation guide appropriate steps respect Scope 3 emissions

 
<>Please provide possible Details significant Scope 3 sources company
evaluation completed estimate significant Scope 3 emissions determined

 
<>b Details metric tonnes CO2 e GHG emissions following categories Employee business travel
<>Our estimate Scope 3 emissions includes colleague travel air rail car rentals commuting evaluating potential emissions based hotel stays

 
<>ii External distribution/logistics
<>Our estimate Scope 3 emissions includes looking downstream logistics distribution services estimate emissions determined significant (i e > 5% total emissions) included Scope 3 inventory parallel Pfizer exploring options measure improve impact logistics operations currently finalizing application requirements participation USEPA’ s SmartWay® Program SmartWay® Transport Partnership innovative collaboration U S EPA freight industry increase energy efficiency significantly reducing greenhouse gases air pollution

 
<>iii Use/disposal company’ s products services
<>We believe Scope 3 emissions disposal company’ s products insignificant determined evaluation estimate

 
<>iv Company supply chain
<>Our estimate Scope 3 emissions include supply chain estimate emissions determined significant (i e > 5% total emissions) anticipate included Scope 3 inventory

 
<>c Details methodology use quantify estimate Scope 3 emissions
detailed evaluation subsequent Scope 3 emissions estimate follows WRI GHG Protocol conducted using relevant emission factors available data good engineering judgment

 
<>Would like provide additional information relating question provided
No 

 
Question 2(d) External Verification
<>(i) information reported response Questions 2(b) (c) beenexternally verified audited plan information verified oraudited
No (Please go to question 2 (e)) 

 
<>(ii) answer question 2d(i) Yes provide attach copy audit verification statement state plans verification

 
<>(iii) specify standard protocol information hasbeen audited verified

 
<>Would like provide additional information relating question provided
No 

 
Question 2(e) Data Accuracy
<>Does company place assess accuracy GHG emissions inventory calculation methods data processes systems relating GHG measurement provide details explain data accuracy managed
Yes, we do have a system. 
Currently Pfizer does externally verify audit GHG emissions inventory party considering option going forward GHG emission inventory methodology approved USEPA Climate Leaders Program GHG emission inventory compiled experienced energy consultant 2007 used team colleagues Global Energy Climate Change Team including representatives EHS engineering groups party consultant (who maintains actual database) assure energy usage emissions data integrity

 
<>Would like provide additional information relating question provided
Yes 
Pfizer member USEPA Climate Leaders program member Climate Leaders partnership minimum Pfizer required Set aggressive corporate wide greenhouse gas (GHG) emissions reduction goal achieved 10 years Perform corporate wide inventory major greenhouse gases (CO2 CH4 N2O HFCs PFCs SF6) completed building inventory step calculating emission reduction goal data collected quality assured external consultant inventory revealed CO2 principal GHG Report annually inventory data USEPA document progress reduction goal USEPA independently verifies data report program participants measures progress achieving reduction target reporting obligations accordance WRI GHG Protocol USEPA Climate Leaders requirements requirements captured Pfizer’ s Inventory Management Plan Pfizer’ s written procedure collecting reporting GHG emissions information Climate Leaders partnership website www epa gov/climateleaders

 
Question 2(f) Emissions History
<>Do emissions reported accounting year vary significantly compared previous years explain reasons variations
Yes, they do vary significantly. 
Pfizer continuing reduce GHG emissions 2007 data illustrates met goal reducing GHG emissions 35% million dollars revenue 2000 baseline downward trend GHG emissions result energy conservation program consisting projects improve energy efficiency facilities global effort raise colleague awareness topics energy conservation climate change efficiency improvements gained consolidation certain operations 2007 Pfizer achieved absolute energy reduction approximately 11% GHG emissions reduction 10% (equivalent 220 000 tCO2e) previous reporting period large portion reduction attributed decreases production levels facilities facility consolidations implementation energy conservation projects initiatives led significant energy consumption GHG emission reductions sale Pfizer’ s Consumer Health Division December 2006 baseline adjustment CO2 emissions accordance IMP

 
<>Would like provide additional information relating question provided
No 

 
Question 2(g) Emissions Trading
<>i) Does company facilities covered EU Emissions Trading Scheme
Yes, our company has facilities covered by the EU ETS. (Please answer 2(g)(i)(a), (b) and (c) and 2(g)(ii).)  

 
<>If a) provide details annual allowances awarded company Phase years 1 January 2005 31 December 2007 details allowances allocated Phase II commencing 1 January 2008 cases enter numbers punctuation example enter 2000 instead 2 000 enter allowance Metric Tonnes CO2 1 January 2005 31 December 2005
128373 Metric Tonnes CO2

 
<>1 January 2006 31 December 2006
133743 Metric Tonnes CO2

 
<>1 January 2007 31 December 2007
136451 Metric Tonnes CO2

 
<>b) provide details actual annual emissions facilities covered EU ETS effect 1 January 2005 enter emissions Metric Tonnes CO2 1 January 2005 31 December 2005
123811 Metric Tonnes CO2

 
<>1 January 2006 31 December 2006
123083 Metric Tonnes CO2

 
<>1 January 2007 31 December 2007
113767 Metric Tonnes CO2

 
<>Phase II annual allowances1 January 2008 – 31 December 2008
130191 Metric Tonnes CO2

 
<>1 January 2009 – 31 December 2009

 
<>1 January 2010 – 31 December 2010

 
<>1 January 2011 – 31 December 2011

 
<>1 January 2012 – 31 December 2012

 
<>c) impact company’ s profitability EU ETS
end 2006 Pfizer transferred small allocation surplus Ireland Sandwich United Kingdom address allocation shortfall Sandwich facility current prediction close operating allocation end year period (2005– 2007) Phase 1 EU ETS Pfizer engaged purchase sale emission units EU ETS seen increase electricity prices European facilities EUETS increases passed electricity providers Pfizer

 
<>ii) company's strategy trading participating regional and/or international trading schemes (eg EU ETS RGGI CCX) Kyoto mechanisms CDM JI projects Explain involvement following EU ETS
Pfizer’ s strategy regard trading carbon preparedness year phase 1 period EU ETS operated allocation did need purchase addition carbon credits explored CDM projects evaluated CDM/JI process feasibility perspective event want explore future opportunities area recently received approval CDM project manufacturing plant India conversion boilers fuel based locally produced sugar cane waste ETS trades date limited internal transfers 2006 companies successfully generate trade energy efficiency credits state Connecticut voluntary market project undertaken demonstrate ability preparedness transactions type (inc 2007) Pfizer implemented projects generate carbon credits (e g EECs RECs) plan sell market researched developed strategies address appropriate financial accounting treatment associated carbon transactions completed review evaluation Climate Leaders Climate Action Partnership (USCAP) Chicago Climate Exchange (CCX) California Climate Registry DOE 1605B Program determine best way position Pfizer regard early action credits Likewise closely monitoring development tracking accounting mechanisms Climate Registry United States seeking manage activities manner position Pfizer carbon constrained regulated economy

 
<>CDM/JI

 
<>CCX

 
<>RGGI

 
<>Others

 
<>Would like provide additional information relating question provided
Yes 
[REFER ATTACHMENT C Tables]

Download attachment
 
Question 2(h) Energy Costs
<>i) identify total costs $ energy consumption fossil fuels electric power want enter number 1 ensure use decimal point (e g 0 3) comma (e g 0 3)
453 US$

 
<>ii) percentage total operating costs does represent
1 %

 
<>iii) percentage energy costs incurred energy renewable sources
2 %

 
<>More details
Pfizer spent $322MM 2007 electricity coal oil natural gas propane facilities spent $6 4MM steam purchased specifically requested CDP believe commodity treated similar way electricity results Scope 2 GHG emissions spent $125MM fuel fleet total fuel cost $453MM Based data Pfizer’ s 2007 Annual Review estimate energy costs represent (1) percent total operating costs $322MM referenced electricity coal oil natural gas propane $199 4MM electricity estimates approximately 2% electricity purchases renewable sources estimate spent $4MM renewable energy includes approximately 0 3% (or $0 5MM) bagasse project implemented India fleet estimate 5% purchased fuel fleet use alternative fuel sources (e g ethanol)

 
<>Would like provide additional information relating question provided
No 

 
3 - Performance
Question 3(a) Reduction Plans
<>i) Does company GHG emissions reduction plan place provide details information requested currently plan place explain
Yes, we have a reduction plan in place. (Please proceed to part (ii) ) 

 
<>ii) baseline year emissions reduction plan
2000

 
<>If want information rolling target
[REFER ATTACHMENT D Graphs][REFER ATTACHMENT C Tables]

 
<>iii) emissions reduction targets period targets extend
Pfizer set public goals related greenhouse gases clean energy Carbon Dioxide (CO2) Generation Goal Reduce CO2 emissions 35% $ million revenue 2007 baseline year 2000 Pfizer set goal participation EPA Climate Leaders Partnership Second Generation Goal reduce worldwide CO2 emissions absolute basis 20% 2008 2012 (baseline year 2007) Clean Energy Goal Meet 35% Pfizer’ s electricity needs 2010 use "clean" energy technologies Clean energy sources defined wind solar biomass hydro cogeneration

 
<>iv) activities undertaking reduce emissions renewable energy energy efficiency process modifications offsets sequestration targets set timescales extend
strategy achieving goals Implement energy conservation projects Pfizer facilities worldwide Increase use clean energy sources Leverage voluntary markets renewable energy energy efficiency provide incentives additional investment energy conservation

 
<>v) investment required achieve targets time period
Generation Goal previously noted Pfizer implemented 1 000 energy conservation projects 2000 2007 capital investment approximately $60MM Second Generation Goal expect investments goal period (2008 2012) similar magnitude generation goal

 
<>vi) emissions reductions associated costs savings achieved date result plan
Pfizer’ s CO2 reduction resulting projects implemented achieve GHG reduction goal total approximately 552 000 MTs CO2eq representing approximately $31MM annual savings portion represents recurring annual savings life project efforts achieve goal Pfizer implemented clean energy projects sites world additional seventeen projects evaluation planning feasibility stage development projects range combined heat power plants photovoltaic systems wind turbines clean energy goal meet 35% Pfizer’ s electricity needs 2010 use "clean" energy technologies (i e wind solar biomass hydro cogeneration) defines program elements minimize use fossil fuels non renewable limited natural resource end 2007 achieved 16% energy clean sources example Singapore facility installed tri generation facility achieved savings 11 175 MT CO2eq

 
<>Would like provide additional information relating question provided
Yes 
[REFER ATTACHMENT C Tables][REFER ATTACHMENT D Graphs]

Download attachment
Download attachment
 
Question 3(b) Emissions Intensity
<>i) appropriate measurement emissions intensity company
Other 
2000 2007 company wide GHG intensity goal indexed million dollars revenue Given myriad product lines different therapeutic areas diversity products believe appropriate intensity measurement operations Going forward absolute GHG reduction goal help advance energy climate change program

 
<>Please company’ s emissions intensity figure measurement given want enter number 1 ensure use decimal point (e g 0 3) comma (e g 0 3)
35

 
<>ii) state GHG emissions intensity terms total tonnes CO2 e reported Scope 1 Scope 2 $m turnover EBITDA reporting year Scope 1/ US$millions turnover
22

 
<>Scope 2/ US$millions turnover
23

 
<>Scope 1/ EBITDA
79

 
<>Scope 2/ EBITDA
85

 
<>iii) company developed emissions intensity targets
Yes, we have developed emission intensity targets. (Please answer questions (a) and (b) below.) 

 
<>a) answer (iii) yes state emissions intensity targets
2000 2007 emissions intensity target 35% reduction GHG emissions $US MM revenue

 
<>b) answer (iii) yes state reductions emissions intensity achieved targets time period
shortly announcing achievement intensity based goal 35% reduction GHG emissions indexed $ MM revenue goal achievement resulted absolute reduction GHG emissions nearly 20% 2000 2007

 
<>Would like provide additional information relating question provided
Yes 
[REFER ATTACHMENT D Graphs]

Download attachment
 
Question 3(c) Planning
<>Do forecast company’ s future emissions and/or energy use
Yes, we do. (Please answer questions (i) to (iii) below.) 

 
<>i) provide details forecasts summarize methodology used assumptions able quantified forecasts Scope 1 Scope 2 emissions and/or electricity consumption enter numerical data page
developing strategy second generation GHG reduction goal detailed analysis undertaken project future emissions based variety factors analysis built 2006 footprint facilities fleet considered growth decline products marketplace time acquisitions expansions closures divestitures efficiencies expected achieved energy conservation efforts outsourcing changes fleet aviation strategies EEC REC markets implementation clean energy projects evaluation resulted emissions forecast years future Based evaluation estimated future emissions Pfizer able propose 20% absolute reduction goal

 
<>ii) factor cost future emissions capital expenditure planning
Pfizer included sale RECs (which effect emissions avoided) financial analysis energy projects price carbon directly incorporated current funding requests revenue generated sale energy efficient credits treated sensitivity certain business cases noted 2007 submission Green Building Team working Pfizer’ s finance organization developed lifecycle cost tool help properly quantify cost value implementing green building enhancements capital spending tool successfully integrated value management capital review process

 
<>iii) considerations impact investment decisions
recognize value enhancing current investment analysis methods include future cost emissions example principles strategies green building design considered retrofit consolidation labs offices Freiburg Germany facility project included evaluations building sustainability operating cost performance environmental economic occupant health impacts building ultimate building design included geothermal heat pump heat insulation building envelope new windows optimization daylight reduced air changes project realizes approximately $440 000/year energy cost savings 2235 MWH reduction gas/fuel reduction 1 200 metric tons CO2 year

 
<>Would like provide additional information relating question provided
No 

 
Question 3(c) (i) Planning Forecasted emissions/electricity use Year 1 answers
page gives opportunity numerical forecasts emissions electricity use possible provide emissions forecasts reporting periods Use “ Add additional year figures” button end page enter emission forecasts successive reporting periods Note enter numbers punctuation example use 2000 instead 2 000
<>Please enter accounting period used report GHG emissions details
Dates selected

 
<>Forecasted Scope 1 Direct GHG Emissions provide Forecasted Total global Scope 1 emissions Metric Tonnes CO2 e

 
<>b Forecasted Total Scope 1 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 1 emissions Metric Tonnes CO2 e individual country Using methodology state emissions forecasts country NB practical list emissions country country basis list countries significant emissions context business combine remainder “ rest world” information format (e g Excel) attach
Country Scope 1 Emissions
(metric tonnes CO2-e)

 
<>Scope 2 Indirect GHG emissions provide c Forecasted total global Scope 2 emissions Metric Tonnes CO2 e

 
<>d Forecasted total Scope 2 emissions Metric Tonnes CO2 e Annex B countries

 
<>By country Forecasted Scope 2 emissions Metric Tonnes CO2 e individual country
Country Scope 2 Emissions
(metric tonnes CO2-e)

 
<>Forecasted electricity consumptione Forecasted total global MWh purchased electricity

 
<>f Forecasted total MWh purchased electricity Annex B countries

 
<>By country – Forecasted MWh purchased electricity individual country
Country

 
<>g Forecasted total global MWh purchased electricity renewable sources

 
<>h Forecasted total MWh purchased electricity renewable sources Annex B countries

 
<>By country – Forecasted MWh purchased electricity renewable sources individual country
Country

 
<>Would like provide additional information relating question provided
No 

 
4 - Governance
Question 4(a) Responsibility
<>Does Board Committee executive body overall responsibility climate change state overall responsibility climate change managed answer parts (i) (ii)
Yes, an executive body does have overall responsibility for climate change. 

 
<>i) Board Committee executive body overall responsibility climate change
Climate change included environment health safety (EHS) management responsibilities Audit Committee Board Pfizer’ s Chief Compliance Officer chairman Company’ s EHS Steering Team comprised Senior Leaders major business operating units

 
<>ii) mechanism Board executive body reviews company’ s progress status regarding climate change
Senior EHS leaders meet EHS Steering Team quarterly basis include progress climate change energy activities Senior EHS leaders meet Pfizer’ s Executive Leadership Team twice year basis review key EHS initiatives including climate change strategy

 
<>Would like provide additional information relating question provided
No 

 
Question 4(b) Individual Performance
<>Do assess provide incentive mechanisms individual management climate change issues including attainment GHG targets provide details
Yes, we do. 
Annual targets vary site site depending number factors particular site typically range 3% 6% Progress site achieving targeted energy efficiency improvement tracked reported regularly year cases actual target incorporated individual’ s performance management plan

 
<>Would like provide additional information relating question provided
No 

 
Question 4(c) Communications
<>Please indicate publish information risks opportunities presented company climate change details GHG emissions plans reduce emissions following communications i) company’ s Annual Report statutory filings
No 

 
<>ii) formal communications shareholders external parties
Yes 
CEO Briefing Document – prepared year Annual Shareholders meeting address potential inquires (includes Q/A Pfizer’ s energy climate change program performance date progress goals) Socially Responsible Investor (SRI) Groups1 Questionnaires Reports (e g DJ Sustainable Asset Management (SAM) SiRi Innovest)2 Individual Requests (e g Walden Asset Management)

 
<>iii) voluntary communications Corporate Social Responsibility reporting
Yes 
Externally accomplish ways Corporate Responsibility Report biennial publicationhttp //www pfizer com/responsibility/values_commitments/corporate_responsibility_report jsphttp //media pfizer com/files/corporate_citizenship/cr_report_2007 pdfUN Global Compact – Communications Progress 10 Principles (received Notable CoP recognition 12/06 submittal)http //www unglobalcompact org/COP/notable_cops htmlhttp //www unglobalcompact org/COP/notable_cops html detail=Pfizer%2C+Inc EPA Climate Leaders – GHG Goal Setting Goal Endorsement GHG Inventory Management Plan GHG Emissions Accountinghttp //www epa gov/stateply/partners/partners/pfizerinc htmlExternal Website – Note 2007 data posted governance process completed (June ’ 08 schedule)www pfizer com/responsibility http //www pfizer com/responsibility/ehs/climate_change_and_energy jsp

 
<>Would like provide additional information relating question provided
Yes 
Speaking Engagements Interviews – e g Pharmaceutical Technology Journalhttp //www ptemag com/pharmtecheurope/Manufacturing+and+Processing/Pharma going greener New Year/ArticleStandard/Article/detail/483080Our Colleagues EHS Ambassadors – assuring knowledge program equipping awareness tools

 
Question 4(d) Public Policy
<>Do engage policymakers possible responses climate change including taxation regulation carbon trading provide details
Yes 
Pfizer determined active engagement policymakers appropriate company time involvement voluntary activities reduce GHG emissions Pfizer hopes build knowledge base adapting mandatory programs reduce compliance costs going forward strengthen position proactive measures rewarded penalized mandatory GHG legislation comes play key aspect ensuring proactive measures rewarded establishment common GHG emissions reporting provide uniform transparent registry verify early actions taken reduce GHGs Pfizer actively tracking development regulation GHG emissions domestic international levels believes mandatory reductions GHGs necessary tackle climate change 2007 Pfizer met USEPA Assistant Administrator Air review Energy Climate Change Program specific challenges industry

 
<>Would like provide additional information relating question provided
Yes 
Pfizer signatory Global Compact Business Leaders’ “ Caring Climate Business Leadership Platform” 2007 confirming belief climate change requires urgent extensive action governments business citizens avoid risk damage global prosperity security addition Pfizer participant strategic influential climate change partnerships proactively manage climate change issues Currently Pfizer member Environmental Protection Agency’ s Climate Leaders industry agency partnership focused developing long term climate change strategies Labs21 voluntary partnership program dedicated improving environmental performance laboratories WRI’ s Climate Northeast partnership northeast mid Atlantic based companies seeking develop climate change management strategies information sharing clean energy investment Business Roundtable’ s Climate RESOLVE encourages industries voluntary actions reduce GHG emissions United State’ s GHG intensity

 
We have upgraded our website login. If you have registered to view CDP responses before December 23, please re-register and we will issue new login details.
  Join the CDP LinkedIn group Follow @cdp on Twitter          Subscribe to receive our monthly newsletter
  Connect with us          Newsletter
   
 
 
  © 2014 CARBON DISCLOSURE PROJECT, Registered Charity no. 1122330.
A company limited by guarantee registered in England no. 05013650